References
- Taher A, Ismaeel H, Cappellini MD. Thalassemia intermedia: revisited. Blood Cells Mol Dis. 2005;37(1):12–20
- Olivieri NF, Muraca GM, O’Donnell A, et al. Studies in Haemoglobin E β-thalassaemia. Br J Haematol. 2008;141(3):388–397
- Hajjar FM, Pearson HA. Pharmacologic treatment of thalassemia intermedia with hydroxyurea. J Pediatr. 1994;125(3):490–492
- Zeng Y-T, Huang S-Z, Ren Z-R, et al. Hydroxyurea therapy in β thalassaemia intermedia: improvement in haematological parameters due to enhanced β globin synthesis. Br J Haematol. 1995;90(3):557–563
- Fucharoen S, Siritanaratkul N, Winichagoon P, et al. Hydroxyurea increases Hb F levels and improves the effectiveness of erythropoiesis in β thalassemia/Hb E disease. Blood. 1996;87(3):887–892
- Loukopoulos D, Voskaridou E, Stamoulakatou A, et al. Hydroxyurea therapy in thalassemia. Ann NY Acad Sci. 1998;850:120–128
- Singer ST, Kuypers FA, Coates TD, et al. The effect of single and combination drug therapy on previously transfused E β-thalassemia patients: implications on decision-making for therapy. Blood. 2002;100(Suppl):119a–120a
- Hashemi A, Abrishamkar M, Jenabzade AR, et al. Hydroxyurea can reduce or eliminate transfusion requirements in children with major and intermediate thalassemia. Iranian J Blood Cancer. 2009;4(4):147–150
- Dolai TK, Dutta S, Bhattacharyya M, Ghosh MK. Prevalence of hemoglobinopathies in rural Bengal, India. Hemoglobin. 2012;36(1):57–63
- Bradai M, Pissard S, Abad MT, et al. Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia. Transfusion. 2007;37(10):1830–1836
- Singer ST, Kuypers FA, Olivieri N, et al. Fetal haemoglobin augmentation in E/β thalassaemia: clinical and haematological outcome. Br J Haematol. 2005;131(3):378–388
- Premawardhena A, Fisher CA, Olivieri NF, et al. Haemoglobin E β thalassaemia in Sri Lanka. Lancet. 2005;366(9495):1467–1470
- Rees DC, Styles L, Vichinsky EP, et al. The Hemoglobin E syndromes. Ann NY Acad Sci. 1998;850:334–343
- Premawardhena A, De Silver S, Arambepola M, et al. Hemoglobin E-β-thalassemia: progress report from the International Study Group. Ann NY Acad Sci. 2005;1054:33–39
- Hoppe C, Vichinsky E, Lewis B, et al. Hydroxyurea and sodium phenylbutyrate therapy in thalassemia intermedia. Am J Hematol. 1999;62(4):221–227
- Karimi M, Darzi H, Yavarian M. Hematologic and clinical responses of thalassemia intermedia patients to hydroxyurea during 6 years of therapy in Iran. J Pediatr Hematol Oncol. 2005;27(7):380–385
- Dixit A, Chatterjea TC, Mishra P, et al. Hydroxyurea in thalassemia intermedia—a promising therapy. Ann Hematol. 2005;84(7):441–446
- Italia KY, Farah Jijina FF, Merchant R, et al. Effect of hydroxyurea on the transfusion requirements in patients with severe Hb E-β-thalassaemia: a genotypic and phenotypic study. Clin Pathol. 2010;63(2):147–150
- Vichinsky EP, Lubin BH. A cautionary note regarding hydroxyurea in sickle cell disease. Blood. 1994;83(4):1124–1128